



VACCINES SUMMIT OHIO

March 1-3, 2021

**SHERATON COLUMBUS HOTEL
AT CAPITOL SQUARE**

75 East State Street Columbus, OH 43215

sachin@bsc.events

(631) 440-0927

Make sure you are at the forefront of the vaccine industry. No matter where your interest lies, we have content, networking and potential partners for you.



PROGRAM AT GLANCE

March
1
Monday

Registrations - 07:00-08:00
Keynote Talks- 08:00-10:00
Coffee Break - 10:00-10:30
Keynote Talks - 10:30-12:30
Lunch Break - 12:30-13:30
Keynote Talks - 13:30-15:30
Coffee Break - 15:30-16:00
Keynote Talks - 16:00- 18:00
Networking Dinner - 19:00-22:00

March
2
Tuesday

Oral Presentations - 08:00 - 10:00
Coffee Break - 10:00-10:30
Oral Presentations - 10:30-12:30
Lunch Break - 12:30-13:30
Oral Presentations - 13:30-15:30
Coffee Break - 15:30-16:00
Poster Presentations - 16:00-18:00

March
3
Wednesday

Oral Presentations - 08:00 - 10:00
Coffee Break - 10:00-10:30
Oral Presentations - 10:30-12:30
Lunch Break - 12:30-13:30
Oral Presentations - 13:30-15:30
Coffee Break - 15:30-16:00
Oral Presentations - 16:00-18:00

About the Vaccines Summit Ohio 2020

Vaccines Summit Ohio (VSOHIO20) is a three-day conference happening in Columbus, OH from March 01-03, 2021. VSOHIO20 will cover a broad range of topics from bacterial vaccines to novel COVID19. The summit will bring together participants from around the globe, including decision-makers, health ministers, UN organizations, NGOs, academia representatives, renowned researchers and healthcare professionals, c-level executives, and social media influencers who actively support vaccination. Three intensive conference days catalyze exponential growth and inspire new solutions and business ideas. VSOHIO20 expands the limits, uniting Vaccine Professionals in Columbus!

The VSOHIO20 provides a great opportunity for researchers and clinicians worldwide to share their work and discuss the latest trends in the field of vaccinology. VSOHIO20 includes the top vaccine influencers in the world, keynotes speakers, informative panels and some of the best networking you'll find all year. The conference is unique in its approach of encouraging a dialogue between speakers and delegates through its well-planned agenda with the series of talks, poster presentations, exhibitions, discussions and networking events that will keep participants engaged in learning.

Scheduled Sessions:

- **Emerging Diseases**
- **Viral Vaccines**
- **Bacterial Vaccines**
- **Animal Models**
- **Influenza Vaccines**
- **Vaccine Safety**
- **Regulatory Science**
- **Clinical Development**
- **Vaccine Hesitancy**
- **HIV Vaccines**
- **Immuno Oncology**
- **New vaccine Development**

Advisory Board Members

Luis Rios-Nogales

Chief Medical Officer, Rational Vaccines, USA

Mahin Khatami

National Cancer Institute (retired), USA

Peter Nara

Chief Scientific Officer, Keystone Bio, USA

S. Louise Cosby

Head of Virology Branch, Agri-Food and Biosciences Institute, UK

Speakers

Gregory A. Poland

Director, Mayo Vaccine Research Group

Mariagrazia Pizza

Senior Scientific Director, GSK Vaccines, Italy

Topic: Bacterial Vaccine

Isis Kanevsky

Associate Director, Pfizer Vaccine, USA

Title: Advances in Bacterial Vaccine Development

Luis Rios-Nogales

Chief Medical Officer, Rational Vaccines, USA

Ahmed Bouzidi

Chief Executive Officer, Immunal Therapeutics, Switzerland

Giulio Tarro

Foundation T. & L. de Beaumont Bonelli for cancer research, Italy

Title: From Polio Vaccines to Oncogenic Viruses

Geert Vanden Bossche

Founder and CSO, Coimeva Llc

Title: Latest Advances in Identifying Target Antigens for Infectious, Immune-mediated and Cancer Diseases

Caroline M. Poland

Founder and President, Poland and Associates Consulting

Topic: Vaccine Hesitancy

Vidadi Yusibov

Director, Research Programs & Sr. Research Fellow, Indiana Biosciences Research Institute, USA

Title: Biomedical Interventions against Substance use Disorders

Stephen Johnston

Director, Center for Innovations in Medicine, Arizona State University, USA

Title: RNA Processing Derived Frameshift Neoantigens for Therapeutic and Preventative Cancer Vaccines

VSOHIO21 Tentative Program

Speakers

Vincent K. Tuohy

Professor, Department of Molecular Medicine, Lerner College of Medicine

Title: Primary Immunoprevention of Adult Onset Cancers

Michael G Hanna

Founder, Director, Chairman Emeritus at Vaccinogen Inc, USA

Title: The Success and Potential of Personal Cancer Vaccines: The Clinical ramifications of Antigen competition driven Immune Editing

Pravin Kaumaya

Director, Vaccine Research, The Ohio State University, USA

Title: Combination of Cancer Vaccines and Immuno-Oncology Strategies

Mahin Khatami

National Cancer Institute (retired), USA

Title: Immune and Bioenergetics of Cancer, Drugs and Vaccines: Future Outlooks

Derek O'Hagan

Head of Global Discovery Support and New Technologies, GSK Vaccines, USA

Topic: RNA Vaccines

Timothy W. Phares

Head of Immunology, Leidos, USA

Title: Peptide-Based Immunomodulators for Vaccines and Therapeutics

M. Javad Aman

President & CSO, Integrated BioTherapeutics

M. Gordon Joyce

Chief, Structural Biology, The Henry M. Jackson Foundation

Title: Structure-based Vaccine Design

Robert DeWitte

Co-founder & CEO, Elarex Inc

Title: Recent Advances in Stabilizing Biologicals and Vaccines.

Martha A. Alexander-Miller

Director Center for Vaccines at the Extremes of Aging, Wake Forest School of Medicine, USA

Title: Development of a Safe and Efficacious Vaccine against Influenza for use in Newborns

Speakers

Larry S. McDaniel

Professor and Chair, Department of Microbiology and Immunology, University of Mississippi Medical Center

Title: Pneumococcal Vaccines and Changing Pneumococcal Ecology

Jung S. Huang

Professor, Saint Louis University School of Medicine, USA

Title: Mammalian LYVE-1, which controls Lymphatic Entry of Immune and Cancer Cells, is a Novel Immune-Oncology Target for Cancer Vaccine and Metastasis-Targeted Therapies

Li Shi

CEO, ZerunBio, China

Title: Development of VLP based EV71 vaccine

Vjollca Konjufca

Southern Illinois University, USA

Title: Induction of immunity in the female reproductive tract by per-oral antigen administration

Michael Lacy

Associate Director, Emergent Biosolutions, USA

James E. Samuel

Wofford Cain Endowed Chair in Infectious Disease, Texas A&M University

Title: Design and evaluation of vaccines against the zoonotic illness, Q fever, in multiple animal infection models

James Lundeen

Founder, Lundon Software, Inc

CEO, President, Sir Issac Newton Enterprises, LLC

Title: Pre-clinical prediction and identification of toxicity based on acid-base titration curve decomposition with advanced data methods.

Pierre A. Morgon

CEO & Founder, MRGN Advisors, Switzerland

Topic: Vaccine Hesitancy

Frédéric J. Deschamps

Professeur, University of Reims, France

Title: Impact of Occupational Risk on Vaccine Coverage

Speakers

Marie Mazur

Vaccine Consultant and Strategic Advisor, USA

Title: Pandemic Influenza: Preparing through Seasonal Readiness

Ming Tan

Assistant Professor, UC Department of Pediatrics

Title: Norovirus Capsid Protein-Derived Nanoparticles as Versatile Platforms for Vaccine Development

De-chu Christopher Tang

Founder CEO; VaxDome Inc.

Title: The nearly-immediate impact of bioengineered adenovirus particles on infection with unrelated pathogens

Rajendar Deora

The Ohio State University, USA

Andrew Lees

Scientific Director and Owner, Fina BioSolutions LLC

Title: Development of EcoCRM® CRM197 Carrier Protein

Robert O. Dillman

Chief Medical Officer, AIVITA Biomedical, Inc.

Title: Human trials testing patient-specific therapeutic vaccines: dendritic cells loaded with antigens from autologous cancer initiating cells

Sabine Hauck

Vice President R&D Leukocare AG

Title: Effective Stabilization of Viral Vaccines and Viral Vector Formulations using an Algorithm based Development Approach

Tilahun Yilma

Professor, University of California Davis

Title: Strategies for Enhancing the Safety and Efficacy of Live Recombinant Vaccines

Magdalena Tary-Lehmann

Chief Scientific Officer, Cellular Technology Limited

Title: Immunogenicity Assessment in Support of Vaccine Therapy Programs- Use of ELISPOT

Speakers

James D. Cherry

Distinguished Research Professor of Pediatrics, Mattel Children's Hospital UCLA

Title: The Problems with Acellular Pertussis Vaccines

Dong Yu

GSK Vaccines

Title: A Self-Amplifying RNA Approach for Vaccine Discovery and Development

Adel Talaat

Professor of Microbiology, University of Wisconsin-Madison

Title: Nanovaccines For Rapid Response to Emerging Infections.

Jiang Zhu

Associate Professor, Department of Integrative Structural and Computational Biology, The Scripps Research Institute

Title: Single-component self-assembling protein nanoparticle (SApNP) vaccines for infectious diseases

David E. Briles

Professor Emeritus, The University of Alabama at Birmingham

Title: Polysaccharide-conjugate vaccines are not able to adequately control pneumococcal meningitis

S. Louise Cosby

Head of Virology Branch, Agri-Food and Biosciences Institute

Title: Large Animal Models for Veterinary and Human Vaccines

Peter Nara

Chief Scientific Officer, Keystone Bio, USA

Title: Decoding Immune evading mechanisms of pathogen's: Re-ordering of immunodominance for improved immunity

**We look forward to
welcoming you in
Columbus, OH**